Clinical data
Routes of
Oral, Insufflated, Rectal
ATC code A08AA (WHO)
Legal status
Legal status
Pharmacokinetic data
Biological half-life 40 hours
Excretion Renal
Synonyms p-Chloro-α,α-dimethylphenethylamine
CAS Number 461-78-9 N 151-06-4
PubChem (CID) 10007
DrugBank DB01556 YesY
ChemSpider 9613 YesY
UNII NHW07912O7 YesY
KEGG C07559 YesY
ECHA InfoCard 100.006.651
Chemical and physical data
Formula C10H14ClN
Molar mass 183.68 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Chlorphentermine (trade names Apsedon, Desopimon, Lucofen) is a serotonergic appetite suppressant of the amphetamine family. Developed in 1962, it is the 4-chloro derivative of the better known appetite suppressant phentermine,[1] which is still in current use.

Chlorphentermine acts as a highly selective serotonin releasing agent (SRA).[2] It is not a psychostimulant and has little or no abuse potential, but is classed as a Schedule III drug in the USA due mainly to its similarity to other appetite suppressants such as diethylpropion which have been more widely abused. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as fenfluramine and aminorex which were found to cause pulmonary hypertension and cardiac fibrosis following prolonged use.[3]

The plasma half-life is about five days.[4] It was withdrawn from the market in the UK in 1974.[4]

See also


  1. Gylys JA, Hart JJ, Warren MR. Chlorphentermine, a new anorectic agent. Journal of Pharmacology and Experimental Therapeutics. 1962 Sep;137:365-73.
  2. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707.
  3. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999 Aug 24;100(8):869-75.
  4. 1 2 Craddock, D (1976). "Anorectic drugs: use in general practice.". Drugs. 11 (5): 378–93. PMID 782835.

This article is issued from Wikipedia - version of the 10/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.